{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:00:22Z","timestamp":1761512422637,"version":"3.37.3"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1124\/dmd.107.016345","type":"journal-article","created":{"date-parts":[[2007,6,29]],"date-time":"2007-06-29T00:54:24Z","timestamp":1183078464000},"page":"1737-1743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["High-Throughput Radiometric CYP2C19 Inhibition Assay Using Tritiated (S)-Mephenytoin"],"prefix":"10.1016","volume":"35","author":[{"given":"Annalise","family":"Di Marco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Cellucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Fonsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.107.016345_bib1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/1389200013338504","article-title":"The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions","volume":"2","author":"Bachmann","year":"2001","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.107.016345_bib2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2165\/00003088-199732030-00004","article-title":"Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions","volume":"32","author":"Bertz","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.107.016345_bib3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15284-1","article-title":"Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450","volume":"27","author":"Busby","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016345_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.phrs.2003.10.010","article-title":"Pharmacokinetic interactions between omeprazole\/pantoprazole and clarithromycin in healthy volunteers","volume":"49","author":"Calabresi","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.107.016345_bib5","first-page":"1","article-title":"Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes","volume":"26","author":"Chauret","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016345_bib6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/dmd.31.8.1005","article-title":"In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates","volume":"31","author":"Cohen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016345_bib7","first-page":"115","article-title":"CYP2C19-mediated (S)-mephenytoin 4\u2032-hydroxylation assayed by high-performance liquid chromatography with radiometric detection","volume":"320","author":"Crespi","year":"2006","journal-title":"Methods Mol Biol"},{"key":"10.1124\/dmd.107.016345_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1056-8719(00)00112-X","article-title":"Fluorometric screening for metabolism-based drug-drug interactions","volume":"44","author":"Crespi","year":"2000","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/dmd.107.016345_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/BF01946135","article-title":"Arene oxides and the NIH shift: the metabolism, toxicity and carcinogenicity of aromatic compounds","volume":"28","author":"Daly","year":"1972","journal-title":"Experientia"},{"key":"10.1124\/dmd.107.016345_bib10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.107.016345_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/dmd.104.002915","article-title":"Development and validation of a high-throughput radiometric CYP2C9 inhibition assay using tritiated diclofenac","volume":"33","author":"Di Marco","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016345_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1124\/dmd.104.002873","article-title":"Development and validation of a high-throughput radiometric CYP3A4\/5 inhibition assay using tritiated testosterone","volume":"33","author":"Di Marco","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016345_bib13","first-page":"299","article-title":"Development of a non-high pressure liquid chromatography assay to determine testosterone hydroxylase (CYP3A) activity in human liver microsomes","volume":"26","author":"Draper","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016345_bib14","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1124\/jpet.106.106013","article-title":"Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism","volume":"318","author":"Galetin","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.016345_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C sub-family","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.107.016345_bib16","first-page":"207","article-title":"Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities","volume":"26","author":"Hickman","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016345_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-3565(25)32651-0","article-title":"Stereoselective metabolism of mephenytoin in man","volume":"218","author":"K\u00fcpfer","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.016345_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-1211(02)00188-2","article-title":"Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19","volume":"52","author":"Lakehal","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1124\/dmd.107.016345_bib19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications","volume":"35","author":"Lin","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.107.016345_bib20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/dmd.31.5.606","article-title":"Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions","volume":"31","author":"Margolis","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016345_bib21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1749-6632.2000.tb06864.x","article-title":"Fluorometric high-throughput screening for inhibitors of cytochrome P450","volume":"919","author":"Miller","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/dmd.107.016345_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0076-6879(82)87032-8","article-title":"Deuterium and tritium kinetic isotope effects on initial rates","volume":"87","author":"Northrop","year":"1982","journal-title":"Methods Enzymol"},{"key":"10.1124\/dmd.107.016345_bib23","first-page":"45","article-title":"The potential pharmacological and toxicological impact of P450 screening","volume":"4","author":"Riley","year":"2001","journal-title":"Curt Opin Drug Discov Devel"},{"key":"10.1124\/dmd.107.016345_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0076-6879(75)37003-1","article-title":"Statistical analysis of radioligand assay data","volume":"37","author":"Rodbard","year":"1975","journal-title":"Methods Enzymol"},{"key":"10.1124\/dmd.107.016345_bib25","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1124\/dmd.30.10.1102","article-title":"Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin","volume":"30","author":"Shin","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016345_bib26","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/00007691-200412000-00009","article-title":"Effects of concomitant fluvoxamine on the plasma concentration of etizolam in Japanese psychiatric patients: wide interindividual variation in the drug interaction","volume":"26","author":"Suzuki","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.107.016345_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.pharmtox.38.1.389","article-title":"In vitro and in vivo drug interactions involving human CYP3A","volume":"38","author":"Thummel","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.107.016345_bib28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016345_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408449209145319","article-title":"The human hepatic cytochromes P450 involved in drug metabolism","volume":"22","author":"Wrighton","year":"1992","journal-title":"Crit Rev Toxicol"},{"key":"10.1124\/dmd.107.016345_bib30","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1124\/dmd.31.5.565","article-title":"Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19","volume":"31","author":"Yao","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.016345_bib31","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1177\/0091270004269015","article-title":"Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes","volume":"44","author":"Yasui-Furukori","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.107.016345_bib32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2125.2003.02047.x","article-title":"Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes","volume":"57","author":"Yasui-Furukori","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.107.016345_bib33","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1124\/dmd.30.12.1311","article-title":"Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions","volume":"30","author":"Yuan","year":"2002","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624014429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624014429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.107.016345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:25:39Z","timestamp":1739895939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624014429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0090955624014429"],"URL":"https:\/\/doi.org\/10.1124\/dmd.107.016345","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-Throughput Radiometric CYP2C19 Inhibition Assay Using Tritiated (S)-Mephenytoin","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.107.016345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}